Top 5 Drug Type | Count |
---|---|
Small molecule drug | 15 |
Exosomes | 2 |
siRNA | 2 |
Other diagnostic agent | 1 |
Monoclonal antibody | 1 |
Target |
Mechanism CCKA agonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. United States |
First Approval Date21 Jul 1976 |
Target |
Mechanism NOX inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism S1P inhibitors |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 May 2025 |
Sponsor / Collaborator |
Start Date24 Mar 2025 |
Sponsor / Collaborator |
Start Date01 Mar 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Isuzinaxib ( NOX ) | Diabetic Nephropathies More | Phase 1 |
Drupanol ( DNA-directed DNA polymerase x HIF-1α x NF-κB ) | Acinetobacter Baumannii Infection More | Preclinical |
TG2-179-1 ( BAP1 ) | Colonic Cancer More | Preclinical |
YTK-2205 ( SQSTM1 ) | Castration-Resistant Prostatic Cancer More | Preclinical |
K-552 ( USP47 ) | KRAS G12C mutant Non-small Cell Lung Cancer More | Preclinical |